Firefly Neuroscience Inc. (NASDAQ: AIFF) announced the identification of an electrophysiological biomarker for Post-Traumatic Stress Disorder using its FDA-cleared Evoke System, according to a company statement.

The biomarker discovery stems from the company's partnership with the U.S. Department of War to assess and treat active-duty service members and veterans with PTSD and Traumatic Brain Injury. The identification uses deep learning architecture running on NVIDIA L40S GPU-accelerated infrastructure to analyze electroencephalogram and Event-Related Potential waveforms.

"By applying our AI models to a dataset that we believe to be unmatched in scale, we have identified a consistent and reproducible electrophysiological pattern distinguishing PTSD patients from healthy controls," said Gil Issachar, the company's Chief Technology Officer.

PTSD affects approximately 13 million Americans annually, with 11-20% of Operation Iraqi Freedom and Enduring Freedom veterans experiencing the condition each year, according to U.S. Department of Veterans Affairs data cited by the company. The total U.S. economic burden of PTSD is estimated at $232.2 billion, with $42.7 billion attributed to military populations.

The company's Evoke System captures both resting-state hyperarousal patterns and cognitive ERP responses through a dual-signal approach. Firefly maintains a database of over 200,000 EEG/ERP brain scans, which it describes as the world's largest standardized repository of such data.

Chief Executive Officer Greg Lipschitz stated the discovery could open commercial pathways in government partnerships, pharmaceutical clinical trials, and clinical psychiatry applications. The biomarker could potentially serve as an objective efficacy endpoint in central nervous system drug development.